Climb Bio releases corporate presentation outlining 2026 clinical milestones
Climb Bio released a corporate presentation in October 2026 detailing the status of its two lead antibody programs, budoprutug and CLYM116. The document outlines the company's mission to develop monoclonal antibody therapeutics for immune-mediated diseases, specifically those affecting kidney health. Climb Bio stated that it is wrapping up a data-rich 2026 with multiple clinical readouts across both programs. The presentation includes extensive forward-looking statements regarding future expectations, plans, and prospects for the company. These statements cover the therapeutic benefits and clinical potential of budoprutug and CLYM116, as well as anticipated timelines for enrolling patients in ongoing and planned clinical trials. The company noted that it has delivered on its 2026 data guidance, with budoprutug readouts for systemic lupus erythematosus and immune thrombocytopenia scheduled to close out the year. Budoprutug is an anti-CD19 monoclonal antibody in development for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The presentation highlights that Fast Track and Orphan Drug Designations have been granted for budoprutug in primary membranous nephropathy. CLYM116 is an anti-APRIL monoclonal antibody in development for IgA nephropathy. Climb Bio identified several key milestones for 2026, including initial Phase 1 healthy volunteer data for budoprutug in May and initial Phase 1 healthy volunteer data for CLYM116 in September. The company also reported initial Phase 1b data for budoprutug in immune thrombocytopenia in June, focusing on B cell and platelet responses in a low-dose cohort. Initial Phase 2 data for budoprutug in primary membranous nephropathy was reported in October, examining B cell and PLA2R levels in a low-dose cohort. The presentation states that Climb Bio is well-resourced to advance its clinical programs through meaningful value-driving milestones. The company anticipates cash runway into the second half of 2028. Climb Bio emphasized that its strategy leverages clinically validated B cell targets, the proven monoclonal antibody modality, and indications with well-defined endpoints and established regulatory pathways. The document warns that forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include the ability to achieve anticipated benefits from a technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd., changes in applicable laws or regulations, and the ability to advance budoprutug and CLYM116 on expected timelines. Other listed risks include obtaining necessary approvals from the U.S. Food and Drug Administration, maintaining intellectual property rights, and raising substantial additional capital needed to continue development. Climb Bio disclaimed any obligation to update forward-looking statements except as required by law. The presentation noted that certain information is based on third-party studies and internal estimates that have not been independently verified. The company stated it has not conducted head-to-head clinical studies comparing its product candidates to any third-party products.
Climb Bio released a corporate presentation in October 2026 detailing the status of its two lead antibody programs, budoprutug and CLYM116. The document outlines the company's mission to develop monoclonal antibody therapeutics for immune-mediated diseases, specifically those affecting kidney health. Climb Bio stated that it is wrapping up a data-rich 2026 with multiple clinical readouts across both programs. The presentation includes extensive forward-looking statements regarding future expectations, plans, and prospects for the company. These statements cover the therapeutic benefits and clinical potential of budoprutug and CLYM116, as well as anticipated timelines for enrolling patients in ongoing and planned clinical trials. The company noted that it has delivered on its 2026 data guidance, with budoprutug readouts for systemic lupus erythematosus and immune thrombocytopenia scheduled to close out the year. Budoprutug is an anti-CD19 monoclonal antibody in development for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The presentation highlights that Fast Track and Orphan Drug Designations have been granted for budoprutug in primary membranous nephropathy. CLYM116 is an anti-APRIL monoclonal antibody in development for IgA nephropathy. Climb Bio identified several key milestones for 2026, including initial Phase 1 healthy volunteer data for budoprutug in May and initial Phase 1 healthy volunteer data for CLYM116 in September. The company also reported initial Phase 1b data for budoprutug in immune thrombocytopenia in June, focusing on B cell and platelet responses in a low-dose cohort. Initial Phase 2 data for budoprutug in primary membranous nephropathy was reported in October, examining B cell and PLA2R levels in a low-dose cohort. The presentation states that Climb Bio is well-resourced to advance its clinical programs through meaningful value-driving milestones. The company anticipates cash runway into the second half of 2028. Climb Bio emphasized that its strategy leverages clinically validated B cell targets, the proven monoclonal antibody modality, and indications with well-defined endpoints and established regulatory pathways. The document warns that forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include the ability to achieve anticipated benefits from a technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd., changes in applicable laws or regulations, and the ability to advance budoprutug and CLYM116 on expected timelines. Other listed risks include obtaining necessary approvals from the U.S. Food and Drug Administration, maintaining intellectual property rights, and raising substantial additional capital needed to continue development. Climb Bio disclaimed any obligation to update forward-looking statements except as required by law. The presentation noted that certain information is based on third-party studies and internal estimates that have not been independently verified. The company stated it has not conducted head-to-head clinical studies comparing its product candidates to any third-party products.